2012 in Review: Tesaro

Before you go, we thought you'd like these...
Before you go close icon

We're rapidly approaching the end of 2012 and, while initial public offerings for tech companies usually grab the headlines, the health care space also had a number of exciting IPOs this year. Not all of them were winners, but Tesaro  is up more than 16% year to date (as of the writing of this article). In the following video, health care analysts Max Macaluso and Brenton Flynn discuss Tesaro's business and drug pipeline.

For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. Will Merck crumble under its own weight, or will it continue to pay dividends to investors for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.


The article 2012 in Review: Tesaro originally appeared on Fool.com.

Brenton FlynnMax Macaluso, Ph.D., and The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners